Tagrisso 80 mg Tagrisso 80 mg contains osimertinib, a targeted anticancer medicine used to treat certain types of non-small cell lung cancer (NSCLC) with specific EGFR gene mutations. It works by blocking abnormal signals that encourage cancer cells to grow and spread. By targeting these mutated proteins, Tagrisso helps slow disease progression while limiting damage to healthy cells.

Effects & Benefits Helps slow the growth and spread of EGFR-positive lung cancer cells. Supports the treatment of advanced or metastatic non-small cell lung cancer. May help reduce the risk of cancer returning after surgery in eligible patients. Can improve disease control and delay cancer progression. Provides a convenient once-daily oral treatment. Helps patients maintain better quality of life when used as prescribed. Possible Side Effects Tagrisso 80 mg should be taken exactly as prescribed by a qualified healthcare professional. The usual recommended dose for most adults is one 80 mg tablet taken once daily. It may be taken with or without food and should be swallowed whole with water. If a dose is missed, it should only be taken if there is sufficient time before the next scheduled dose. The treatment duration depends on the patient's condition and response to therapy. Regular medical check-ups and monitoring are important throughout the course of treatment.